EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board

Dr. DeFelice is the Founder and Chairman of the Foundation for Innovation in Medicine and a leading authority on nutraceutical products worldwide.

Jan 29, 2010, 14:12 ET from EP Global Communications, Inc.

JOHNSTOWN, Pa., Jan. 29 /PRNewswire-FirstCall/ -- EP Global Communications, Inc. (EPGL), (the Company), (Pink Sheets: EPGL), (www.eparent.com), the parent company of Exceptional Parent (EP) magazine, is proud to announce that Stephen L. DeFelice, MD, has joined the EPGL Advisory Board. Dr. DeFelice is one of the world's leading authorities on nutraceutical products and is credited for introducing the term "nutraceutical." 

"This addition to our team of experts will enable EPGL to more authoritatively evaluate and provide accurate and scientifically sound information about the multitude of products offered in the vast arena of nutraceuticals and indeed unique medical devices," stated the Company's President and CEO, Joseph M. Valenzano, Jr.  "EP Global Communications intends to use its multitude of relationships in the healthcare, pharmaceutical, and biotech industries and its impeccable reputation for science-based, credible information to objectively review those products which can have a positive effect on the lives of people with disabilities and special healthcare needs and their families and caregivers."  

Stephen L. DeFelice, MD is the Founder and Chairman of the Foundation for Innovation in Medicine (FIM), a nonprofit organization established in 1976 with the purpose of accelerating medical discovery by establishing a more productive clinical research community.  A graduate of Temple University, Dr. DeFelice received his MD from Jefferson Medical College in Philadelphia. He was a National Institute of Health (NIH) fellow in endocrinology, diabetes, and metabolic disease at Jefferson and a fellow in clinical pharmacology at St. Vincent's Hospital and Medical Center in New York City. Dr. DeFelice is the former Chief of Clinical Pharmacology at the Walter Reed Army Institute of Research (WRAIR). His 35-year experience with carnitine, a naturally occurring substance with multiple medical benefits, sparked his interest and determination to encourage medical discovery. His experience taught him that the promise of medical technology is exploding, but the barriers, costs, and risks of clinically testing their promise, a critical step in medical discovery, are also exploding.

In 1972, Dr. DeFelice wrote the book Drug Discovery: The Pending Crisis (Medcom Press) to alert the US to the fact that medical discovery was and would continue to be significantly delayed because of the formidable barriers to conducting clinical research. He first proposed the idea of physician volunteers or "doctornauts" (a term he coined) who would be more free than others to volunteer for clinical research. This simple act would lead to the clinical testing of more potential medical discoveries.

Today, FIM is involved in two initiatives: the Nutraceutical Research and Education Act (NREA) and the need for Congress to enact the Doctornaut Act. Senator Bill Frist (R-TN) has expressed a strong interest in the latter concept.

About EP Global Communications, Inc.

EP Global Communications, Inc., parent company of Exceptional Parent (EP) magazine, is a 39-year-old, award-winning, multi-media publishing and communications company, providing timely and indispensable resources and information to families and professionals caring for the needs of children and adults with disabilities and special health care needs, including families in the U.S. Military.

Safe Harbor Statement

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE EP Global Communications, Inc.



RELATED LINKS

http://www.eparent.com